WO2024086789A3 - Mutant pi3k-alpha inhibitors and their use as pharmaceuticals - Google Patents

Mutant pi3k-alpha inhibitors and their use as pharmaceuticals Download PDF

Info

Publication number
WO2024086789A3
WO2024086789A3 PCT/US2023/077410 US2023077410W WO2024086789A3 WO 2024086789 A3 WO2024086789 A3 WO 2024086789A3 US 2023077410 W US2023077410 W US 2023077410W WO 2024086789 A3 WO2024086789 A3 WO 2024086789A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceuticals
alpha inhibitors
mutant pi3k
pi3k
mutant
Prior art date
Application number
PCT/US2023/077410
Other languages
French (fr)
Other versions
WO2024086789A2 (en
Inventor
Andrew Paul Combs
Andrew W. BUESKING
Chun Chen
Ryan Holmes
Soham Maity
Original Assignee
Prelude Therapeutics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Incorporated filed Critical Prelude Therapeutics Incorporated
Publication of WO2024086789A2 publication Critical patent/WO2024086789A2/en
Publication of WO2024086789A3 publication Critical patent/WO2024086789A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.
PCT/US2023/077410 2022-10-20 2023-10-20 Mutant pi3k-alpha inhibitors and their use as pharmaceuticals WO2024086789A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263380270P 2022-10-20 2022-10-20
US63/380,270 2022-10-20

Publications (2)

Publication Number Publication Date
WO2024086789A2 WO2024086789A2 (en) 2024-04-25
WO2024086789A3 true WO2024086789A3 (en) 2024-06-06

Family

ID=90738398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/077410 WO2024086789A2 (en) 2022-10-20 2023-10-20 Mutant pi3k-alpha inhibitors and their use as pharmaceuticals

Country Status (1)

Country Link
WO (1) WO2024086789A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
US20170360795A1 (en) * 2013-05-30 2017-12-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20210253601A1 (en) * 2009-06-29 2021-08-19 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2021202964A1 (en) * 2020-04-03 2021-10-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
US20210253601A1 (en) * 2009-06-29 2021-08-19 Incyte Corporation Pyrimidinones as pi3k inhibitors
US20170360795A1 (en) * 2013-05-30 2017-12-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2021202964A1 (en) * 2020-04-03 2021-10-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIN MINHANG, DUAN WEIMING, FENG YIFAN, HEI YUAN-YUAN, ZHANG HAO, SHEN YING, ZHAO HONG-YI, MAO SHUAI, ZHANG SAN-QI: "Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 33, no. 1, 1 January 2018 (2018-01-01), GB , pages 651 - 656, XP093182027, ISSN: 1475-6366, DOI: 10.1080/14756366.2018.1444608 *

Also Published As

Publication number Publication date
WO2024086789A2 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
MX2023003264A (en) Cdk inhibitors and their use as pharmaceuticals.
TNSN03110A1 (en) Azaindoles.
MX2023007265A (en) Cdk inhibitors and their use as pharmaceuticals.
WO2004037212A3 (en) Compositions comprising zopiclone derivatives and methods of making and using the same
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
BRPI0409227B8 (en) "compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (i)"
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
MX2007006744A (en) Hydantoin derivatives useful as metalloproteinase inhibitors.
MX2022013984A (en) Inhibitors of nek7 kinase.
MX2023009052A (en) Biphenyl compound as immunomodulator, preparation method therefor and use thereof.
MX2023003846A (en) Biphenyl compound as immunomodulator, preparation method therefor and application thereof.
MX2022015495A (en) Inhibitors of nek7 kinase.
AU2003263498A1 (en) Pyrazole derivatives
CA3156320A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists
WO2024086789A3 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
AU2003242592A1 (en) Amide derivatives as inhibitors of the enzymatic activity of renin
WO2022140428A3 (en) Inhibitors of peptidylarginine deiminases
MX2023011464A (en) Nek7 inhibitors.
WO2021055797A9 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA200600022A1 (en) APPLICATION OF DERIVATIVE BICYCLO [2.2.1] HEPTANA TO PREPARE NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS
MX2022013890A (en) Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof.
WO2024149340A1 (en) Indolone derivative having irak4 inhibitory activity, and preparation method therefor and use thereof
WO2003004460A3 (en) Succinic acid derivatives
WO2023150592A3 (en) N3-substituted uracil compounds as trpa1 inhibitors
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23880845

Country of ref document: EP

Kind code of ref document: A2